Literature DB >> 2405549

Cyclosporine-induced hypertension in sheep. The role of thromboxanes.

J J Tresham1, J A Whitworth, B A Scoggins, W M Bennett.   

Abstract

Thromboxanes have been implicated in the CsA-induced hemodynamic changes and impairment in renal function in humans and in rats. We have previously shown that administration of intravenous CsA to sheep for 5 days at 12 mg/kg/day produces a hypertension that is resistance mediated and independent of nephrotoxicity. In this study we used a thromboxane synthetase inhibitor, U63,557A, to examine the role of thromboxanes in the CsA-induced hypertension in the sheep. The thromboxane synthetase inhibitor had no effect on blood pressure in normotensive sheep. Serum thromboxane levels were not elevated with CsA, and the inhibitor had a minimal effect on blood pressure during CsA treatment, suggesting that thromboxanes are not a major contributor to the rise in blood pressure seen in the sheep. A study of the dose-response relationship for CsA at 3, 6, and 24 mg/kg/day for 5 days indicated that maximal blood pressure responses were attained with 6 mg/kg/day.

Entities:  

Mesh:

Substances:

Year:  1990        PMID: 2405549     DOI: 10.1097/00007890-199001000-00032

Source DB:  PubMed          Journal:  Transplantation        ISSN: 0041-1337            Impact factor:   4.939


  2 in total

1.  Acute cardiovascular effects of intravenous cyclosporine.

Authors:  J F Navarro; C Mora; R Marcén; J L Teruel; C Gámez; J J Jiménez; L Orofino; J Ortuño
Journal:  Int Urol Nephrol       Date:  1996       Impact factor: 2.370

2.  HNF4alpha dysfunction as a molecular rational for cyclosporine induced hypertension.

Authors:  Monika Niehof; Jürgen Borlak
Journal:  PLoS One       Date:  2011-01-27       Impact factor: 3.240

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.